The Division of Molecular Imaging and Therapeutics at the Weill Cornell Medical (WCM)/NewYork-Presbyterian Hospital (NYPH) is composed of physicians, physicists, engineers, pharmacists, chemists, and mathematicians who work closely together and uses imaging probes to diagnose and treat disease.
Over the last several decades, this has evolved into increasingly precise evaluations of patients with lymphoma, prostate cancer, neuroendocrine neoplasm, cardiac disease, dementia and metastatic disease. These precise tools are essential for multiple clinical trials with antibodies and small molecules tagged with Lutetium-177, Yttrium-90 and Actinium 225. At the moment, we provide multiple Prostate Cancer therapies with radiolabeled PSMA in conjunction with genitourinary oncology, multiple PET and PET/MR probes investigating Dementia and Neurooncology and are beginning several investigations in Endocrine oncology.
Our equipment includes 3 state-of-the-art PET/MRI scanners, 5 PET/CT scanners, 2 general purpose SPECT/CT and 4 general-purpose SPECT devices in the hospital, outpatient clinic, and the imaging research center.
The Division is associated with the MI4 laboratory which connects clinical care to database mining, preclinical studies and phase 0/1 studies where pharmacokinetic and pharmacodynamics studies will be performed. The MI4 space is building capacity to support early clinical with their required analysis of blood or urine-based correlatives. The radiopharmaceutical facilities are staffed by 5 PhD level radiochemists, 4 full time radiopharmacists, and support staff to maintain active programs in clinical practice and research.
There is a state-of-the-art cyclotron in the Citicorp Biomedical Imaging Center (CBIC) and multiple hot cells to produce high quality radiopharmaceuticals with a variety of radioisotopes, including Carbon-11, Nitrogen-13, Fluorine 18, Zirconium-87, and Iodine-124, among others. Small animal PET and SPECT cameras are available to facilitate non-clinical research.
Our vision for the future sees nuclear medicine as a central component of personalized medicine. Our field is continuously developing new radiopharmaceuticals for characterizing the molecular biology of individual patients. We already deliver unique information that matters, and seem well positioned to help patients capitalize on rapidly emerging innovations in many fields of medicine.